2.32
-0.04 (-1.69%)
| Penutupan Terdahulu | 2.36 |
| Jumlah Dagangan | 3,115 |
| Harga / Jualan (P/S) | 10.60 |
| Harga / Buku (P/B) | 0.930 |
| Julat 52 Minggu |
| Margin Keuntungan | -146.13% |
| Margin Operasi (TTM) | -2,226.82% |
| EPS Cair (TTM) | -1.01 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -98.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.80% |
| Nisbah Semasa (MRQ) | 15.64 |
| Aliran Tunai Operasi (OCF TTM) | -5.60 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.83 M |
| Pulangan Atas Aset (ROA TTM) | -17.60% |
| Pulangan Atas Ekuiti (ROE TTM) | -24.89% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Lipocine Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.00 |
|
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP’RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 2.95% |
| % Dimiliki oleh Institusi | 9.73% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Seven Fleet Capital Management Lp | 30 Jun 2026 | 78,842 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |